



WHO grants Emergency Use Listing to Covaxin

03 November 2021 | News

Covaxin is the first Indian vaccine to be approved by WHO

The World Health Organisation (WHO) has granted emergency use listing (EUL) to COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, "The EUL authorisation for COVAXIN® will enable us to contribute to accelerating the equitable access of COVID-19 vaccine, and the access to our vaccine globally thereby addressing the current public health emergency."

This is in addition to the recent announcement made by the Therapeutic Goods Administration (TGA) in Australia that has determined that Covaxin would be 'recognised' for the purpose of establishing a traveller's vaccination status.

Also, the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of COVAXIN up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO. The shelf life extension has been communicated to our stakeholders.